The goal of this research was to characterize a population of patients who were treated with low-grade serous ovarian/peritoneal carcinoma (LGSOC) at a modern primary care facility, with an emphasis on recurrence and disease-free survival factors. Participants included 99 women with stage II-IV ovarian or peritoneal LGSOC who had undergone cytoreductive surgery and either platinum/taxane chemotherapy followed by aromatase inhibitor maintenance therapy or aromatase inhibitor monotherapy for primary treatment and for whom clinical data was available. Clinico-demographic characteristics were described using descriptive statistics. Survival rates and progression-free intervals were compared between subgroups.
Research using multivariate Cox regression models was conducted. The median progression-free survival for the whole group was 56.8 months (95% CI, 41.3-NE), and the median overall survival was 130.7 months (95% CI, 115.0-146.4). To date, 49 patients (49.5%) have experienced a recurrence. The median time until relapse among these 49 individuals was 29.6 months (95% CI, 24.6-33.1) (range, 5.4–69.1 months). Only 1 in every 49 individuals who relapsed (2% of the total) did so more than 5 years after their initial diagnosis. About 50 patients, or 50.0%, have shown no signs of disease worsening or relapse. These 50 patients have been followed for a median of 86.2 months (range, 25.3–169.0).
About 33 (66.0%) of the 50 had follow-up care for more than 5 years after their diagnosis. No substantial residual disease, a normal blood CA 125 at diagnosis, a primary peritoneal location, and the presence of significant psammomatous calcifications were all factors in regression analyses that were related to improved patient outcomes (PFS, OS, or both). Women with stages II-IV LGSOC who were treated with current primary therapy are described for the first time, together with their clinicopathologic characteristics and results.
Source: sciencedirect.com/science/article/abs/pii/S0090825822005911
